Milameline is a non-selective muscarinic acetylcholine receptor partial agonist with cognition-acting properties that had being investigated for the treatment of Alzheimer's disease. References: Trollor JN, Sachdev PS, Haindl W, Brodaty H, Wen W, Walker BM. Combined cerebral blood flow effects of a cholinergic agonist (milameline) and a verbal recognition task in early Alzheimer's disease. Psychiatry Clin Neurosci. 2006 Oct;60(5):616-25. PubMed PMID: 16958947. 2: Jack CR Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, Xu Y, Shiung M, O'Brien PC, Cha R, Knopman D, Petersen RC. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology. 2003 Jan 28;60(2):253-60. PubMed PMID: 12552040; PubMed Central PMCID: PMC2745302. 3: Zheng XM. Detecting regional cerebral blood flow changes in Alzheimer's patients after milameline treatment: activation or baseline SPECT? J Nucl Med Technol. 2002 Sep;30(3):118-22. PubMed PMID: 12186960. 4: Schwarz RD, Callahan MJ, Coughenour LL, Dickerson MR, Kinsora JJ, Lipinski WJ, Raby CA, Spencer CJ, Tecle H. Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization. J Pharmacol Exp Ther. 1999 Nov;291(2):812-22. PubMed PMID: 10525104. 5: Callahan MJ. Combining tacrine with milameline reverses a scopolamine-induced impairment of continuous performance in rhesus monkeys. Psychopharmacology (Berl). 1999 Jun;144(3):234-8. PubMed PMID: 10435389.

纯度：≥98%

CAS：139886-04-7